-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
Radalbuvir
![{PARAM:[Name]}({[CAS]})](https://resource.bocsci.com/structure/1314795-11-3.gif)
| Category | Hepatitis C Virus (HCV) |
| CAS | 1314795-11-3 |
| Description | Radalbuvir is a Hepatitis C virus NS 5 protein inhibitor for the treatment of hepatitis C virus (HCV) infection developed by Gilead Sciences. In 2014, Gilead completed a phase II trial for Hepatitis C in USA. |
Product Information
| Synonyms | GS-9669; GS 9669; GS9669; Radalbuvir;5-(3,3-dimethyl-1-butyn-1-yl)-3-((cis-4-hydroxy-4-((((3S)-tetrahydro-3-furanyl)oxy)methyl)cyclohexyl)(((1R)-4-methyl-3-cyclohexen-1-yl)carbonyl)amino)- 2-Thiophenecarboxylic acid |
| IUPAC Name | 5-(3,3-dimethylbut-1-ynyl)-3-[[4-hydroxy-4-[[(3S)-oxolan-3-yl]oxymethyl]cyclohexyl]-[(1R)-4-methylcyclohex-3-ene-1-carbonyl]amino]thiophene-2-carboxylic acid |
| Molecular Weight | 543.72 |
| Molecular Formula | C30H41NO6S |
| Canonical SMILES | CC1=CC[C@@H](CC1)C(=O)N([C@@H]2CC[C@@](O)(CO[C@H]3CCOC3)CC2)c4cc(C#CC(C)(C)C)sc4C(=O)O |
| InChI | 1S/C30H41NO6S/c1-20-5-7-21(8-6-20)27(32)31(25-17-24(11-13-29(2,3)4)38-26(25)28(33)34)22-9-14-30(35,15-10-22)19-37-23-12-16-36-18-23/h5,17,21-23,35H,6-10,12,14-16,18-19H2,1-4H3,(H,33,34)/t21-,22-,23-,30+/m0/s1 |
| InChIKey | MUICUPWICXUNRS-GDCCIXDYSA-N |
| Boiling Point | 721.2±60.0 °C at 760 mmHg |
| Flash Point | 389.9±32.9 °C |
| Purity | 98% |
| Density | 1.3±0.1 g/cm3 |
| Solubility | Soluble in DMSO |
| Appearance | Powder |
| Application | Hepatitis C |
| Shelf Life | 2 month in rt, long time |
| Storage | -20°C Freezer |
| Complexity | 966 |
| Exact Mass | 543.26545920 |
| Index Of Refraction | 1.599 |
| In Vitro | Radalbuvir (GS-9669) shows high in vitro Metabolic stability, long residence time in rats, and maintained high activity against the NS5B M423T mutation (GT1b M423T EC50 = 14 nM). |
| Target | HCV |
| Vapor Pressure | 0.0±2.4 mmHg at 25°C |
| XLogP3-AA | 4.7 |